The Experts below are selected from a list of 7818 Experts worldwide ranked by ideXlab platform
Takumi Ochiai - One of the best experts on this subject based on the ideXlab platform.
-
identification of responders non responders to 5 fluorouracil based on individual 50 inhibitory area under the concentration Curve of 5 fluorouracil obtained with collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Oncology Letters, 2011Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Tadasuke Hashiguchi, Takayuki Uchida, Naoki Sakuyama, Tsuyoshi SatoAbstract:We previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells obtained from colorectal cancer (CRC) patients using the collagen gel droplet-embedded culture-drug sensitivity test (CD-DST). Multiple drug concentrations and contact durations, and the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. Moreover, the individualized AUC(IR50), the AUC value which gives 50% growth inhibition, was calculated using the AUC-IR Curve. This study aimed to identify responders/non-responders to 5-FU based on the individual AUC(IR50) obtained with CD-DST in order to establish individualized chemotherapy for CRC patients. The individual AUC(IR50) was calculated from each AUC-inhibition rate regression Curve in all patients using the CD-DST. The cumulative distribution of the individual AUC(IR50) in CRC patients was evaluated. The cumulative distribution of the individual AUC(IR50) was regressed over the sigmoid Curve (Logarithmic scale). The approximate expression was almost exactly y=ab^exp(-cx) (a=0.9739, b=1.7096E-21, c=0.8990, the sum of square residuals, 0.0279). In the 80 cases examined, no notable change was observed in the regression Curve when the number of patients increased. A standard Curve was obtained describing responders to 5-FU among all CRC patients. From this standard Curve, we ascertained that non-responders accounted for approximately 5% of all patients. Moreover, we were able to classify responders into good or intermediate responders to 5-FU. The standard Curve describing response to 5-FU in CRC patients offers a useful tool in the establishment of individualized chemotherapy.
-
evaluation of the individual 50 inhibitory area under the concentration Curve of 5 fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Molecular Medicine Reports, 2009Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Masataka Tsuji, Noboru Nakayama, Satomi Mashiko, Isao NagaokaAbstract:We have previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells from colorectal cancer (CRC) patients using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) under multiple drug concentrations and contact durations. Moreover, the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. In the present study, we used the AUC-IR Curve to calculate the individualized AUCIR50, the AUC value that imparts 50% growth inhibition. Individual AUCIR50 was calculated in CRC patients, and its distribution was evaluated. The cumulative distribution of individual AUCIR50 was regressed over two lines (Logarithmic scale). Among the 45 resectable CRC patients, those who achieved more than the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated a trend towards better disease-free survival compared to those who did not achieve AUCIR50. Of the Dukes' D patients (n=10), those who achieved more than twice the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated significantly better survival rates (p=0.05) than those who did not. In this study, the distribution of the individual AUCIR50 suggested that approximately 6% of patients demonstrated very low 5-FU sensitivity. Therefore, the individual AUCIR50 was useful in classifying good, intermediate and poor 5-FU response. Achievement of the individual AUCIR50 may be a prerequisite for individualized 5-FU-based adjuvant chemotherapy. As well, the early achievement of twice the individual AUCIR50 may indicate an improved prognosis in Dukes' D patients. The individual AUCIR50 using CD-DST is useful in determining the individualized chemotherapy of CRC patients, thus CD-DST has the potential to facilitate the establishment of individualized chemotherapy for CRC.
Isao Nagaoka - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of the individual 50 inhibitory area under the concentration Curve of 5 fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Molecular Medicine Reports, 2009Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Masataka Tsuji, Noboru Nakayama, Satomi Mashiko, Isao NagaokaAbstract:We have previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells from colorectal cancer (CRC) patients using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) under multiple drug concentrations and contact durations. Moreover, the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. In the present study, we used the AUC-IR Curve to calculate the individualized AUCIR50, the AUC value that imparts 50% growth inhibition. Individual AUCIR50 was calculated in CRC patients, and its distribution was evaluated. The cumulative distribution of individual AUCIR50 was regressed over two lines (Logarithmic scale). Among the 45 resectable CRC patients, those who achieved more than the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated a trend towards better disease-free survival compared to those who did not achieve AUCIR50. Of the Dukes' D patients (n=10), those who achieved more than twice the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated significantly better survival rates (p=0.05) than those who did not. In this study, the distribution of the individual AUCIR50 suggested that approximately 6% of patients demonstrated very low 5-FU sensitivity. Therefore, the individual AUCIR50 was useful in classifying good, intermediate and poor 5-FU response. Achievement of the individual AUCIR50 may be a prerequisite for individualized 5-FU-based adjuvant chemotherapy. As well, the early achievement of twice the individual AUCIR50 may indicate an improved prognosis in Dukes' D patients. The individual AUCIR50 using CD-DST is useful in determining the individualized chemotherapy of CRC patients, thus CD-DST has the potential to facilitate the establishment of individualized chemotherapy for CRC.
Masayuki Kitajima - One of the best experts on this subject based on the ideXlab platform.
-
identification of responders non responders to 5 fluorouracil based on individual 50 inhibitory area under the concentration Curve of 5 fluorouracil obtained with collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Oncology Letters, 2011Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Tadasuke Hashiguchi, Takayuki Uchida, Naoki Sakuyama, Tsuyoshi SatoAbstract:We previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells obtained from colorectal cancer (CRC) patients using the collagen gel droplet-embedded culture-drug sensitivity test (CD-DST). Multiple drug concentrations and contact durations, and the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. Moreover, the individualized AUC(IR50), the AUC value which gives 50% growth inhibition, was calculated using the AUC-IR Curve. This study aimed to identify responders/non-responders to 5-FU based on the individual AUC(IR50) obtained with CD-DST in order to establish individualized chemotherapy for CRC patients. The individual AUC(IR50) was calculated from each AUC-inhibition rate regression Curve in all patients using the CD-DST. The cumulative distribution of the individual AUC(IR50) in CRC patients was evaluated. The cumulative distribution of the individual AUC(IR50) was regressed over the sigmoid Curve (Logarithmic scale). The approximate expression was almost exactly y=ab^exp(-cx) (a=0.9739, b=1.7096E-21, c=0.8990, the sum of square residuals, 0.0279). In the 80 cases examined, no notable change was observed in the regression Curve when the number of patients increased. A standard Curve was obtained describing responders to 5-FU among all CRC patients. From this standard Curve, we ascertained that non-responders accounted for approximately 5% of all patients. Moreover, we were able to classify responders into good or intermediate responders to 5-FU. The standard Curve describing response to 5-FU in CRC patients offers a useful tool in the establishment of individualized chemotherapy.
-
evaluation of the individual 50 inhibitory area under the concentration Curve of 5 fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Molecular Medicine Reports, 2009Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Masataka Tsuji, Noboru Nakayama, Satomi Mashiko, Isao NagaokaAbstract:We have previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells from colorectal cancer (CRC) patients using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) under multiple drug concentrations and contact durations. Moreover, the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. In the present study, we used the AUC-IR Curve to calculate the individualized AUCIR50, the AUC value that imparts 50% growth inhibition. Individual AUCIR50 was calculated in CRC patients, and its distribution was evaluated. The cumulative distribution of individual AUCIR50 was regressed over two lines (Logarithmic scale). Among the 45 resectable CRC patients, those who achieved more than the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated a trend towards better disease-free survival compared to those who did not achieve AUCIR50. Of the Dukes' D patients (n=10), those who achieved more than twice the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated significantly better survival rates (p=0.05) than those who did not. In this study, the distribution of the individual AUCIR50 suggested that approximately 6% of patients demonstrated very low 5-FU sensitivity. Therefore, the individual AUCIR50 was useful in classifying good, intermediate and poor 5-FU response. Achievement of the individual AUCIR50 may be a prerequisite for individualized 5-FU-based adjuvant chemotherapy. As well, the early achievement of twice the individual AUCIR50 may indicate an improved prognosis in Dukes' D patients. The individual AUCIR50 using CD-DST is useful in determining the individualized chemotherapy of CRC patients, thus CD-DST has the potential to facilitate the establishment of individualized chemotherapy for CRC.
Kazuhiko Nishimura - One of the best experts on this subject based on the ideXlab platform.
-
identification of responders non responders to 5 fluorouracil based on individual 50 inhibitory area under the concentration Curve of 5 fluorouracil obtained with collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Oncology Letters, 2011Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Tadasuke Hashiguchi, Takayuki Uchida, Naoki Sakuyama, Tsuyoshi SatoAbstract:We previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells obtained from colorectal cancer (CRC) patients using the collagen gel droplet-embedded culture-drug sensitivity test (CD-DST). Multiple drug concentrations and contact durations, and the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. Moreover, the individualized AUC(IR50), the AUC value which gives 50% growth inhibition, was calculated using the AUC-IR Curve. This study aimed to identify responders/non-responders to 5-FU based on the individual AUC(IR50) obtained with CD-DST in order to establish individualized chemotherapy for CRC patients. The individual AUC(IR50) was calculated from each AUC-inhibition rate regression Curve in all patients using the CD-DST. The cumulative distribution of the individual AUC(IR50) in CRC patients was evaluated. The cumulative distribution of the individual AUC(IR50) was regressed over the sigmoid Curve (Logarithmic scale). The approximate expression was almost exactly y=ab^exp(-cx) (a=0.9739, b=1.7096E-21, c=0.8990, the sum of square residuals, 0.0279). In the 80 cases examined, no notable change was observed in the regression Curve when the number of patients increased. A standard Curve was obtained describing responders to 5-FU among all CRC patients. From this standard Curve, we ascertained that non-responders accounted for approximately 5% of all patients. Moreover, we were able to classify responders into good or intermediate responders to 5-FU. The standard Curve describing response to 5-FU in CRC patients offers a useful tool in the establishment of individualized chemotherapy.
-
evaluation of the individual 50 inhibitory area under the concentration Curve of 5 fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Molecular Medicine Reports, 2009Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Masataka Tsuji, Noboru Nakayama, Satomi Mashiko, Isao NagaokaAbstract:We have previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells from colorectal cancer (CRC) patients using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) under multiple drug concentrations and contact durations. Moreover, the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. In the present study, we used the AUC-IR Curve to calculate the individualized AUCIR50, the AUC value that imparts 50% growth inhibition. Individual AUCIR50 was calculated in CRC patients, and its distribution was evaluated. The cumulative distribution of individual AUCIR50 was regressed over two lines (Logarithmic scale). Among the 45 resectable CRC patients, those who achieved more than the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated a trend towards better disease-free survival compared to those who did not achieve AUCIR50. Of the Dukes' D patients (n=10), those who achieved more than twice the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated significantly better survival rates (p=0.05) than those who did not. In this study, the distribution of the individual AUCIR50 suggested that approximately 6% of patients demonstrated very low 5-FU sensitivity. Therefore, the individual AUCIR50 was useful in classifying good, intermediate and poor 5-FU response. Achievement of the individual AUCIR50 may be a prerequisite for individualized 5-FU-based adjuvant chemotherapy. As well, the early achievement of twice the individual AUCIR50 may indicate an improved prognosis in Dukes' D patients. The individual AUCIR50 using CD-DST is useful in determining the individualized chemotherapy of CRC patients, thus CD-DST has the potential to facilitate the establishment of individualized chemotherapy for CRC.
Akinori Nakatani - One of the best experts on this subject based on the ideXlab platform.
-
identification of responders non responders to 5 fluorouracil based on individual 50 inhibitory area under the concentration Curve of 5 fluorouracil obtained with collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Oncology Letters, 2011Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Tadasuke Hashiguchi, Takayuki Uchida, Naoki Sakuyama, Tsuyoshi SatoAbstract:We previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells obtained from colorectal cancer (CRC) patients using the collagen gel droplet-embedded culture-drug sensitivity test (CD-DST). Multiple drug concentrations and contact durations, and the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. Moreover, the individualized AUC(IR50), the AUC value which gives 50% growth inhibition, was calculated using the AUC-IR Curve. This study aimed to identify responders/non-responders to 5-FU based on the individual AUC(IR50) obtained with CD-DST in order to establish individualized chemotherapy for CRC patients. The individual AUC(IR50) was calculated from each AUC-inhibition rate regression Curve in all patients using the CD-DST. The cumulative distribution of the individual AUC(IR50) in CRC patients was evaluated. The cumulative distribution of the individual AUC(IR50) was regressed over the sigmoid Curve (Logarithmic scale). The approximate expression was almost exactly y=ab^exp(-cx) (a=0.9739, b=1.7096E-21, c=0.8990, the sum of square residuals, 0.0279). In the 80 cases examined, no notable change was observed in the regression Curve when the number of patients increased. A standard Curve was obtained describing responders to 5-FU among all CRC patients. From this standard Curve, we ascertained that non-responders accounted for approximately 5% of all patients. Moreover, we were able to classify responders into good or intermediate responders to 5-FU. The standard Curve describing response to 5-FU in CRC patients offers a useful tool in the establishment of individualized chemotherapy.
-
evaluation of the individual 50 inhibitory area under the concentration Curve of 5 fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer
Molecular Medicine Reports, 2009Co-Authors: Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Masataka Tsuji, Noboru Nakayama, Satomi Mashiko, Isao NagaokaAbstract:We have previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells from colorectal cancer (CRC) patients using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) under multiple drug concentrations and contact durations. Moreover, the area under the concentration Curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR Curve, which was approximated to the Logarithmic Curve. In the present study, we used the AUC-IR Curve to calculate the individualized AUCIR50, the AUC value that imparts 50% growth inhibition. Individual AUCIR50 was calculated in CRC patients, and its distribution was evaluated. The cumulative distribution of individual AUCIR50 was regressed over two lines (Logarithmic scale). Among the 45 resectable CRC patients, those who achieved more than the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated a trend towards better disease-free survival compared to those who did not achieve AUCIR50. Of the Dukes' D patients (n=10), those who achieved more than twice the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated significantly better survival rates (p=0.05) than those who did not. In this study, the distribution of the individual AUCIR50 suggested that approximately 6% of patients demonstrated very low 5-FU sensitivity. Therefore, the individual AUCIR50 was useful in classifying good, intermediate and poor 5-FU response. Achievement of the individual AUCIR50 may be a prerequisite for individualized 5-FU-based adjuvant chemotherapy. As well, the early achievement of twice the individual AUCIR50 may indicate an improved prognosis in Dukes' D patients. The individual AUCIR50 using CD-DST is useful in determining the individualized chemotherapy of CRC patients, thus CD-DST has the potential to facilitate the establishment of individualized chemotherapy for CRC.
